Shanxi Zhendong PharmaceuticalLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shanxi Zhendong PharmaceuticalLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	18.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Improved Revenues Required Before Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Stock's 39% Jump Looks Justified

Oct 22

We Think Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Can Afford To Drive Business Growth

Sep 30

Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Low P/S No Reason For Excitement

Aug 08

Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Mar 07

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanxi Zhendong PharmaceuticalLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:300158 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	3,112	-3	-414	-137	N/A
6/30/2024	3,200	-28	-382	-173	N/A
3/31/2024	3,457	-20	-236	-52	N/A
12/31/2023	3,626	-44	-365	-249	N/A
9/30/2023	3,713	-77	-192	-47	N/A
6/30/2023	3,936	-61	282	425	N/A
3/31/2023	3,791	-61	-355	-212	N/A
1/1/2023	3,729	-51	-64	81	N/A
9/30/2022	3,841	2,319	-177	-43	N/A
6/30/2022	4,173	2,421	-291	-131	N/A
3/31/2022	4,689	2,529	430	572	N/A
1/1/2022	5,094	2,617	133	284	N/A
9/30/2021	5,528	378	166	329	N/A
6/30/2021	5,520	365	-137	41	N/A
3/31/2021	5,196	299	-163	24	N/A
12/31/2020	4,848	262	38	222	N/A
9/30/2020	4,653	208	-6	101	N/A
6/30/2020	4,401	154	82	141	N/A
3/31/2020	4,445	152	132	159	N/A
12/31/2019	4,399	143	167	186	N/A
9/30/2019	4,155	-67	390	422	N/A
6/30/2019	3,772	-133	399	425	N/A
3/31/2019	3,546	-147	324	343	N/A
12/31/2018	3,420	-147	131	154	N/A
9/30/2018	3,746	120	109	136	N/A
6/30/2018	3,738	233	N/A	74	N/A
3/31/2018	3,786	295	N/A	-71	N/A
12/31/2017	3,732	302	N/A	45	N/A
9/30/2017	3,702	343	N/A	-107	N/A
6/30/2017	3,777	330	N/A	-182	N/A
3/31/2017	3,504	243	N/A	-10	N/A
12/31/2016	3,283	203	N/A	-45	N/A
9/30/2016	2,688	117	N/A	97	N/A
6/30/2016	2,383	67	N/A	202	N/A
3/31/2016	2,323	67	N/A	72	N/A
12/31/2015	2,262	65	N/A	152	N/A
9/30/2015	2,165	51	N/A	58	N/A
6/30/2015	2,199	43	N/A	75	N/A
3/31/2015	2,010	40	N/A	74	N/A
12/31/2014	1,919	42	N/A	73	N/A
9/30/2014	1,673	56	N/A	-53	N/A
6/30/2014	1,711	70	N/A	-36	N/A
3/31/2014	1,695	68	N/A	-31	N/A
12/31/2013	1,658	74	N/A	-75	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 300158's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if 300158's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 300158's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 300158's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 300158's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 300158's Return on Equity is forecast to be high in 3 years time

Shanxi Zhendong PharmaceuticalLtd Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: CN¥0.009 (vs CN¥0.018 loss in 3Q 2023)

Improved Revenues Required Before Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Stock's 39% Jump Looks Justified

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 24, 2024

We Think Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Can Afford To Drive Business Growth

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board and Non-Employee Supervisor Elections

Second quarter 2024 earnings released: EPS: CN¥0.007 (vs CN¥0.014 in 2Q 2023)

Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Low P/S No Reason For Excitement

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 27, 2024

High number of new directors

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.043 loss per share (vs CN¥0.05 loss in FY 2022)

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 23, 2024

Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Now 20% undervalued

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.018 loss per share (vs CN¥0 in 3Q 2022)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: CN¥0.014 (vs CN¥0.015 in 2Q 2022)

Full year 2022 earnings released: CN¥0.05 loss per share (vs CN¥2.55 profit in FY 2021)

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0 (vs CN¥0.10 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.015 (vs CN¥0.12 in 2Q 2021)

Upcoming dividend of CN¥2.70 per share

Investor sentiment improved over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 09 May 2022

No independent directors

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves 2021 Profit Distribution Plan

Investor sentiment deteriorated over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 22, 2022

Shanxi Zhendong Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.087 in 3Q 2020)

Investor sentiment deteriorated over the past week

FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. entered into an agreement to acquire Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) for CNY 5.8 billion.

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.055 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Final Profit for 2020

Shanxi Zhendong Pharmaceutical Co.,Ltd Announces Final Profit Distribution Proposal for 2020

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.14 in FY 2019)

New 90-day low: CN¥4.39

Investor sentiment deteriorated over the past week

New 90-day low: CN¥5.46

New 90-day low: CN¥5.73

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q3, 2020 Results on Oct 27, 2020

New 90-day high - CN¥6.39

New 90-day high - CN¥6.05

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 21, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies